{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:31:01Z","timestamp":1780929061705,"version":"3.54.1"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Vaccines of enhanced range of protection could help to control newly emerging infectious diseases while providing greater resilience to any subsequent variants. Such \u201cuniversal vaccines\u201d are an idealized, but unrealized, goal that may benefit from unbiased, high-throughput approaches that define antibody cross-reactivity to enable rational selection of cross-protective epitopes. The priority of this investigation is to establish a pipeline for the identification and preliminary characterization of epitopes with enhanced cross-reactivity. A peptide immunoarray representing the proteomes of SARS-CoV, SARS-CoV-II, and MERS-CoV was applied to characterize spike glycoprotein-specific antibody populations within convalescence serum of SARS-CoV-II infected ferrets. Through two alternate bioinformatic approaches, twenty candidate epitopes were identified and translated into vaccines. Epitopes inducing antibodies with cross-reactivity across naturally occurring versions of spike glycoprotein, including SARS-CoV-II Delta and Omicron variants, as well as antigenically distant SARS-CoV and MERS-CoV, were identified. Working from the assumption that cross-reactivity is prerequisite for cross-protection, this highlights the opportunity and mechanisms by which immunoarrays, coupled with <jats:italic><jats:italic>in vitro<\/jats:italic><\/jats:italic> screening assays, can enable rational selection of epitopes with enhanced potential for cross-protection.<\/jats:p>","DOI":"10.1371\/journal.pone.0330741","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:33:41Z","timestamp":1757007221000},"page":"e0330741","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity"],"prefix":"10.1371","volume":"20","author":[{"given":"Zo\u00eb Parker","family":"Cates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Facciuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Scruten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kusalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-4538","authenticated-orcid":true,"given":"Scott","family":"Napper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"9","key":"pone.0330741.ref001","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"OJ Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pone.0330741.ref002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","article-title":"Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022","volume":"11","author":"N Wu","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"pone.0330741.ref003","doi-asserted-by":"crossref","first-page":"2002083","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson","volume":"18","author":"R Patel","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"pone.0330741.ref004","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3390\/cells9122638","article-title":"Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2","volume":"9","author":"MM Hatmal","year":"2020","journal-title":"Cells"},{"issue":"1","key":"pone.0330741.ref005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"FX Heinz","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"2","key":"pone.0330741.ref006","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","article-title":"Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population","volume":"29","author":"JJ Lau","year":"2023","journal-title":"Nat Med"},{"issue":"10283","key":"pone.0330741.ref007","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","article-title":"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)","volume":"397","author":"VJ Hall","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"pone.0330741.ref008","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2207082","article-title":"Protection against Omicron from Vaccination and Previous Infection in a Prison System","volume":"387","author":"ET Chin","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0330741.ref009","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/cid\/ciab608","article-title":"An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status","volume":"74","author":"SF Lumley","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"22","key":"pone.0330741.ref010","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMc2211283","article-title":"Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose","volume":"387","author":"M Canetti","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"pone.0330741.ref011","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMc2210093","article-title":"Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa","volume":"387","author":"S Collie","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0330741.ref012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.15585\/mmwr.mm7104e3","article-title":"Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022","volume":"71","author":"MG Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"pone.0330741.ref013","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"R Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"pone.0330741.ref014","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1080\/21645515.2016.1191718","article-title":"Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets","volume":"12","author":"R Serv\u00edn-Blanco","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"pone.0330741.ref015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/08830185.2019.1685990","article-title":"Current challenges: from the path of \u201coriginal antigenic sin\u201d towards the development of universal flu vaccines","volume":"39","author":"A Biswas","year":"2020","journal-title":"Int Rev Immunol"},{"issue":"5","key":"pone.0330741.ref016","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2123477119","article-title":"Researchers getting closer to a \u201cuniversal\u201d flu vaccine","volume":"119","author":"C Beans","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0330741.ref017","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1038\/s41467-024-50345-6","article-title":"Cytomegalovirus vaccine vector-induced effector memory CD4\u2009+\u2009T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge","volume":"15","author":"D Malouli","year":"2024","journal-title":"Nat Commun"},{"key":"pone.0330741.ref018","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jneuroim.2012.09.014","article-title":"Feasibility of an early Alzheimer\u2019s disease immunosignature diagnostic test","volume":"254","author":"L Restrepo","year":"2013","journal-title":"J Neuroimmunol"},{"issue":"4","key":"pone.0330741.ref019","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1074\/mcp.M115.051664","article-title":"High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients","volume":"15","author":"M Hecker","year":"2016","journal-title":"Mol Cell Proteomics"},{"issue":"28","key":"pone.0330741.ref020","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1016\/j.vaccine.2010.04.061","article-title":"A general method for characterization of humoral immunity induced by a vaccine or infection","volume":"28","author":"JB Legutki","year":"2010","journal-title":"Vaccine"},{"issue":"46","key":"pone.0330741.ref021","doi-asserted-by":"crossref","first-page":"18614","DOI":"10.1073\/pnas.1309390110","article-title":"Immunosignatures can predict vaccine efficacy","volume":"110","author":"JB Legutki","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0330741.ref022","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1038\/s41598-022-12032-8","article-title":"High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection","volume":"12","author":"A Facciuolo","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"pone.0330741.ref023","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/eji.202049101","article-title":"Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development","volume":"51","author":"P Holenya","year":"2021","journal-title":"Eur J Immunol"},{"issue":"1","key":"pone.0330741.ref024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tibtech.2012.10.012","article-title":"Immunosignaturing: a critical review","volume":"31","author":"KF Sykes","year":"2013","journal-title":"Trends Biotechnol"},{"issue":"4","key":"pone.0330741.ref025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/03009858211071012","article-title":"Ferrets are valuable models for SARS-CoV-2 research","volume":"59","author":"M Ciurkiewicz","year":"2022","journal-title":"Vet Pathol"},{"issue":"8","key":"pone.0330741.ref026","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"M Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"pone.0330741.ref027","doi-asserted-by":"crossref","first-page":"694324","DOI":"10.3389\/fbinf.2021.694324","article-title":"EPIphany-A Platform for Analysis and Visualization of Peptide Immunoarray Data","volume":"1","author":"Z Parker Cates","year":"2021","journal-title":"Front Bioinform"},{"key":"pone.0330741.ref028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/msb.2011.75","article-title":"Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega","volume":"7","author":"F Sievers","year":"2011","journal-title":"Mol Syst Biol"},{"key":"pone.0330741.ref029","volume-title":"Manual on setting up, using, and understanding random forests v3.1","author":"L Breiman","year":"2002"},{"key":"pone.0330741.ref030","volume-title":"Breiman and Cutlers Random Forests for Classification and Regression","author":"LCA Breiman","year":"2022"},{"key":"pone.0330741.ref031","volume-title":"Estimating the global economic costs of SARS","author":"JW MW. Lee","year":"2004"},{"key":"pone.0330741.ref032","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy213","article-title":"The Economic and Social Burden of the 2014 Ebola Outbreak in West Africa","volume":"218","author":"C Huber","year":"2018","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0330741.ref033","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1089\/hs.2018.0115","article-title":"Economic Impact of the 2015 MERS Outbreak on the Republic of Korea\u2019s Tourism-Related Industries","volume":"17","author":"H Joo","year":"2019","journal-title":"Health Secur"},{"issue":"31","key":"pone.0330741.ref034","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1016\/j.vaccine.2010.05.031","article-title":"The 2009 A (H1N1) influenza virus pandemic: A review","volume":"28","author":"MP Girard","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"pone.0330741.ref035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s12276-021-00603-0","article-title":"The evolution and future of influenza pandemic preparedness","volume":"53","author":"WN Harrington","year":"2021","journal-title":"Exp Mol Med"},{"issue":"8029","key":"pone.0330741.ref036","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-024-07766-6","article-title":"Pathogenicity and transmissibility of bovine H5N1 influenza virus","volume":"633","author":"AJ Eisfeld","year":"2024","journal-title":"Nature"},{"issue":"2","key":"pone.0330741.ref037","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2202669","article-title":"Delivering Pandemic Vaccines in 100 Days - What Will It Take?","volume":"387","author":"M Saville","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0330741.ref038","first-page":"193","article-title":"SARS Immunity and Vaccination","volume":"1","author":"M Zhu","year":"2004","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"pone.0330741.ref039","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1086\/500469","article-title":"Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome","volume":"193","author":"W Liu","year":"2006","journal-title":"J Infect Dis"},{"issue":"6","key":"pone.0330741.ref040","doi-asserted-by":"crossref","DOI":"10.3201\/eid2206.160010","article-title":"Antibody Response and Disease Severity in Healthcare Worker MERS Survivors","volume":"22","author":"AN Alshukairi","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"pone.0330741.ref041","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3201\/eid2210.160706","article-title":"Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus","volume":"22","author":"DC Payne","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"pone.0330741.ref042","doi-asserted-by":"crossref","first-page":"6491738","DOI":"10.1155\/2019\/6491738","article-title":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development","volume":"2019","author":"A Mubarak","year":"2019","journal-title":"J Immunol Res"},{"issue":"10229","key":"pone.0330741.ref043","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","article-title":"Middle East respiratory syndrome","volume":"395","author":"ZA Memish","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"pone.0330741.ref044","doi-asserted-by":"crossref","first-page":"1729683","DOI":"10.1080\/19420862.2020.1729683","article-title":"Understanding the human antibody repertoire","volume":"12","author":"AR Rees","year":"2020","journal-title":"MAbs"},{"issue":"23","key":"pone.0330741.ref045","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1093\/bioinformatics\/btm493","article-title":"Pepitope: epitope mapping from affinity-selected peptides","volume":"23","author":"I Mayrose","year":"2007","journal-title":"Bioinformatics"},{"issue":"14","key":"pone.0330741.ref046","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/bioinformatics\/btv136","article-title":"EpIC: a rational pipeline for epitope immunogenicity characterization","volume":"31","author":"K Marciniuk","year":"2015","journal-title":"Bioinformatics"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:33:48Z","timestamp":1757007228000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330741"}},"subtitle":[],"editor":[{"given":"Rishi","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330741","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]}}}